Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...

Traders have long known Donald Trump intended to use tariffs as a tool for economic policy. Citigroup Inc., a year ago, even ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance ...

The stock's rise snapped a four-day losing streak.

Former Edwards Lifesciences Critical Care Unit, renamed BD Advanced Patient Monitoring, yesterday launched the HemoSphere ...

Grist journalists share how we investigated this story and how to learn more about ethylene oxide emissions in your area.

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that ...